You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
SARS-COV-2 (COVID-19), NAAT |
||||||||||||||||||||||||||||||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3777 Geisinger Epic ID: 137323 | |||||||||||||||||||||||||||||
SPECIMEN COLLECTION |
||||||||||||||||||||||||||||||
Specimen type: |
See table below: | |||||||||||||||||||||||||||||
Specimen required: |
|
|||||||||||||||||||||||||||||
Special notes: |
Check expiration date on collection/transport device before use. Refer to Virology Collection Appendix for collection instructions. | |||||||||||||||||||||||||||||
| SPECIMEN PROCESSING |
||||||||||||||||||||||||||||||
Transport temperature: |
Specimens in UTM or sterile container: Refrigerated (2-8°C). Aptima® Multitest Swab specimens can be transported at room temperature or refrigerated. |
|||||||||||||||||||||||||||||
Specimen stability: |
UTM or saline Flocked Swab Specimens: Stable at 4°C for up to 72 hours after collection. Stable for 24 hours at room temperature (15-25°C).
Aptima® Multitest Swab specimens: Stable 6 days at room temperature and up to 3 months at 2-8°C. Specimens in sterile containers: Stable at 2-8°C for up to 72 hours. |
|||||||||||||||||||||||||||||
Rejection criteria: |
Specimens stored or transported at incorrect temperature. Swab specimens not in transport medium. Improperly labeled/identified specimens. Specimens collected on wooden shafted swab. Expired transport medium. Specimens which exceed stability limits. Insufficient specimen volume. Inappropriate specimen type. Swab specimens should be collected only on swabs with a synthetic tip (such as polyester or Dacron®) with aluminum or plastic shafts. Swabs with calcium alginate or cotton tips with wooden shafts are not acceptable. |
|||||||||||||||||||||||||||||
TEST DETAILS |
||||||||||||||||||||||||||||||
Reference interval: |
Negative. No 2019 Novel Coronavirus detected. | |||||||||||||||||||||||||||||
Additional information: |
A false negative result may occur if inadequate numbers of organisms are present in the specimen due to improper collection, transport, or handling. | |||||||||||||||||||||||||||||
CPT code(s): |
U0003 or U0004 (depending on method used). | |||||||||||||||||||||||||||||
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||||||||||||||||||||||||||||||
Test includes: |
Molecular detection of RNA from approved respiratory specimens. This assay uses real-time polymerase chain reaction (RT-PCR) for in vitro qualitative detection of SARS-CoV-2 in nasopharyngeal specimens. | |||||||||||||||||||||||||||||
Methodology: |
Real-time Polymerase Chain Reaction (PCR) Transcription-Mediated Amplification (TMA) |
|||||||||||||||||||||||||||||
Synonyms: |
Comprehensive viral studies, viral culture, PCR, respiratory pathogen (PCR), coronavirus, COVID-19, COVID, nCoV, SARS-CoV-2, SARS-CoV-2, MOLECULAR DETECTION, RESPIRATORY– (2019- nCoV) CORONAVIRUS NCOV19
|
|||||||||||||||||||||||||||||
Clinical significance: |
Respiratory pathogens cause acute local and systemic disease of varying severity, with the most severe cases occurring in children, the elderly, and immunocompromised individuals. Due to the similarity of diseases caused by many viruses and bacteria, diagnosis based on clinical symptoms alone is difficult. Identification of potential causative agents provides data to aid the physician to determine appropriate patient treatment and public health response for disease containment. | |||||||||||||||||||||||||||||
Doctoral Director(s:) |
Donna Wolk PhD, D(ABMM), Raquel Martinez, PhD, D(ABMM) | |||||||||||||||||||||||||||||
| Review Date: | 12/31/2022 | |||||||||||||||||||||||||||||